Large holder notice
Open the filing on sec.gov
ENDRA Life Sciences Inc. (NDRA)
Nasdaq: NDRA · Electromedical & Electrotherapeutic Apparatus · Ann Arbor, MI · filing with the SEC since 2016
The companyfiscal 2020, as filed
Revenue$0.00
Net income-$11.7M+11.9%
Earnings per share$-0.63
Operating cash flow-$10.7M-25.1%
Cash$7.2M
Debtn/a
Shareholders’ equity$7.2M+50.6%
Shares, dilutedn/a
Return on equity-310.9%
The recordfrom its filings
Filings in 202648
Newest filingNov 10 · SCHEDULE 13G
Annual reportMar 31, 2026
Quarterly reportAug 14, 2026
Next report due10-Q by Nov 14
Insider sales, 12 months$0.00
Insider buys, 12 months$0.00
Patents granted38
Filer categoryNon-accelerated filer<br>Smaller reporting company
Trailing twelve months to Jun 2026Net income -$5.9MCash from operations -$4.8Mthe four newest filed quarters added
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
As filed, in USD. Nothing here is a forecast.
News
Merger communication
Open the filing on sec.gov
Merger communication
Open the filing on sec.gov
Merger communication
Open the filing on sec.gov
Insider holding, initial
Open the filing on sec.gov
Activist holder notice
Open the filing on sec.gov
Merger or exchange registration
Open the filing on sec.gov
Merger communication
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Merger communication
Open the filing on sec.gov
Nothing of this kind is on the record for this company yet.
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.